Cargando…

PD-1 as a potential target in cancer therapy

Recently, an improved understanding of the molecular mechanisms governing the host response to tumors has led to the identification of checkpoint signaling pathways involved in limiting the anticancer immune response. One of the most critical checkpoint pathways responsible for mediating tumor-induc...

Descripción completa

Detalles Bibliográficos
Autores principales:	McDermott, David F, Atkins, Michael B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Science Inc 2013
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892798/ https://www.ncbi.nlm.nih.gov/pubmed/24403232 http://dx.doi.org/10.1002/cam4.106

Ejemplares similares

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer
por: Chen, James L, et al.
Publicado: (2013)

PD‐L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer
por: Ji, Xiaoyu, et al.
Publicado: (2021)

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis
por: Yang, Yuanquan, et al.
Publicado: (2022)

A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status
por: Izar, Benjamin, et al.
Publicado: (2017)

Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers
por: Kaneko, Kensuke, et al.
Publicado: (2022)

Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer
por: Ghonim, Mohamed A, et al.
Publicado: (2021)

The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysis
por: Wang, Bi‐Cheng, et al.
Publicado: (2019)

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2021)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
por: Teng, Meng‐Meng, et al.
Publicado: (2021)

Prognostic significance of the radiologic features of pneumonitis induced by anti‐PD‐1 therapy
por: Watanabe, Satoshi, et al.
Publicado: (2020)

Higher preoperative serum levels of PD‐L1 and B7‐H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF‐targeted therapy and unfavorable prognosis of renal cell carcinoma
por: Fukuda, Takehiko, et al.
Publicado: (2016)

Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers
por: Shao, Yilin, et al.
Publicado: (2021)

Alterations of DNA damage response genes correlate with response and overall survival in anti‐PD‐1/PD‐L1‐treated advanced urothelial cancer
por: Joshi, Monika, et al.
Publicado: (2020)

Prostasin regulates PD-L1 expression in human lung cancer cells
por: Chen, Li-Mei, et al.
Publicado: (2021)

Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis
por: Geng, Yichao, et al.
Publicado: (2021)

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC
por: Lesueur, Paul, et al.
Publicado: (2018)

PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions
por: Xia, Liliang, et al.
Publicado: (2019)

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
por: Schetters, Sjoerd T T, et al.
Publicado: (2020)

Prognostic and immune regulating roles of YIF1B in Pan-Cancer: a potential target for both survival and therapy response evaluation
por: Liu, Jun, et al.
Publicado: (2020)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
por: Chen, Yu, et al.
Publicado: (2021)

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
por: Gao, Hannan, et al.
Publicado: (2020)

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
por: Regan, Meredith M, et al.
Publicado: (2021)

Prognostic significance of T‐cell–inflamed gene expression profile and PD‐L1 expression in patients with esophageal cancer
por: Steiniche, Torben, et al.
Publicado: (2021)

Antitumor efficacy of (90)Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors
por: Potluri, Hemanth K, et al.
Publicado: (2022)

Prognostic implication of PD‐L1 polymorphisms in non‐small cell lung cancer treated with radiotherapy
por: Kang, Min Kyu, et al.
Publicado: (2021)

Advances in IKBKE as a potential target for cancer therapy
por: Yin, Min, et al.
Publicado: (2019)

High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer
por: Ito, Masaaki, et al.
Publicado: (2019)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy
por: Dharmapuri, Sirish, et al.
Publicado: (2020)

CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
por: Xiao, Minglu, et al.
Publicado: (2022)

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence
por: Byeon, Seonggyu, et al.
Publicado: (2020)

PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling
por: Gao, Hongmin, et al.
Publicado: (2019)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
por: Koller, Paul, et al.
Publicado: (2023)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials
por: Yun, Seongseok, et al.
Publicado: (2016)

PD‐L1 and PD1 expression in post‐transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter‐ and intra‐individual descriptive study covering the whole spectrum of PTLD categories
por: Schiefer, Ana‐Iris, et al.
Publicado: (2019)

Off‐label prescribing of targeted anticancer therapy at a large pediatric cancer center
por: Lim, Mir, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fvniq0ibqnkvndm1qi7kaj734l